BRIEF—Mage Bio launches with focus on oral antibody therapy

Healthcare investor TVM Capital Life Science has joined forces with Tillotts Pharma to launch a new biotech company, Mage Biologics, backed by $28 million in financing.

The company will begin work on a novel, orally administered, monoclonal antibody which has been developed by Tillotts as part of a collaboration with Numab Therapeutics.

Utilizing Tillotts’ sustained release approach, the antibody will be developed for the treatment of ulcerative colitis initially.

Tillotts chief executive Thomas Tóth von Kiskér said: “The collaboration with TVM underpins Tillotts’ leading role in developing and commercializing innovative products in the gastrointestinal field.”

Mage will be led by Tillotts scientific affairs head Johannes Spleiss, with Chantal Miklosi serving as chief financial officer.

Tillotts Pharma is part of the Japanese Zeria Group.